Lonza and Integral Molecular will collaborate to better assess the risks of off-target binding of biologic drug candidates.
Lonza and Integral Molecular recently announced a strategic collaboration wherein they will work together to assess the risks of off-target binding of biologic drug candidates. The collaboration aims to provide a better method of assessing immunogenicity, immunotoxicity, and cross-reactivity potential early in a biologic’s development cycle.
According to a press release from April 25, 2022, the companies feel that their respective expertise complement one another in this endeavor. Lonza’s early development services focuses on cell-based assays, which evaluate the activity of biologic therapies upon binding. Integral Molecular, on the other hand, detects off-target binding liabilities via its Membrane Proteome Array platform.
“Early immunogenicity de-risking significantly increases chances of the future success of therapies as they progress through the development pathway,” said Yvette Stallwood, head of early development services, Lonza, in the press release. “Lonza’s 14 years of expertise in in-silico and in-vitro immunogenicity and immunotoxicity assessments complements Integral Molecular’s valuable insights into off-target binding using [its] Membrane Proteome Array.”
“We are pleased to offer complementary expertise to Lonza’s cell-based assay experience for preclinical safety profiling of biologics, thereby offering drug developers a more complete evaluation methodology to select the optimal candidate to move forward to IND [investigational new drug] filing.” said Benjamin Doranz, CEO and co-founder, Integral Molecular, in the press release.
Source: Integral Molecular
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.